170 related articles for article (PubMed ID: 15837560)
1. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease.
Miller TW; Zhou C; Gines S; MacDonald ME; Mazarakis ND; Bates GP; Huston JS; Messer A
Neurobiol Dis; 2005; 19(1-2):47-56. PubMed ID: 15837560
[TBL] [Abstract][Full Text] [Related]
2. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
[TBL] [Abstract][Full Text] [Related]
4. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
5. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
7. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain.
Toneff T; Mende-Mueller L; Wu Y; Hwang SR; Bundey R; Thompson LM; Chesselet MF; Hook V
J Neurochem; 2002 Jul; 82(1):84-92. PubMed ID: 12091468
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
Tebbenkamp AT; Green C; Xu G; Denovan-Wright EM; Rising AC; Fromholt SE; Brown HH; Swing D; Mandel RJ; Tessarollo L; Borchelt DR
Hum Mol Genet; 2011 Jul; 20(14):2770-82. PubMed ID: 21515588
[TBL] [Abstract][Full Text] [Related]
9. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation.
Havel LS; Wang CE; Wade B; Huang B; Li S; Li XJ
Hum Mol Genet; 2011 Apr; 20(7):1424-37. PubMed ID: 21245084
[TBL] [Abstract][Full Text] [Related]
10. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
[TBL] [Abstract][Full Text] [Related]
11. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
[TBL] [Abstract][Full Text] [Related]
12. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
13. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.
Butler DC; Messer A
PLoS One; 2011; 6(12):e29199. PubMed ID: 22216210
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
Wolfgang WJ; Miller TW; Webster JM; Huston JS; Thompson LM; Marsh JL; Messer A
Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11563-8. PubMed ID: 16061794
[TBL] [Abstract][Full Text] [Related]
15. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
16. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin.
Waldron-Roby E; Ratovitski T; Wang X; Jiang M; Watkin E; Arbez N; Graham RK; Hayden MR; Hou Z; Mori S; Swing D; Pletnikov M; Duan W; Tessarollo L; Ross CA
J Neurosci; 2012 Jan; 32(1):183-93. PubMed ID: 22219281
[TBL] [Abstract][Full Text] [Related]
18. Clearance of mutant huntingtin.
Li XJ; Li H; Li S
Autophagy; 2010 Jul; 6(5):663-4. PubMed ID: 20519964
[TBL] [Abstract][Full Text] [Related]
19. Sustained effects of nonallele-specific Huntingtin silencing.
Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
[TBL] [Abstract][Full Text] [Related]
20. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
